a large cohort of patients of the reported study should enable the clinicians to develop a personalized dose titration scheme in the individual patients treated with Pegvaliase to avoid severe hypersensitivity reactions and to ensure efficacy of the drug, i.e., reduction of blood Phenylalanine levels. PKU patients, who qualify for this new treatment option, will have to be informed that due to the induction of antibodies a wide range of hypersensitivity reactions can occur in the early phase of treatment with Pegvaliase and that -in contrast to conventional treatment strategies-blood Phe levels will only slowly decrease after starting the new drug treatment. Obviously, in clinical practice, this new treatment option will require close monitoring of efficacy and safety of the drug by the responsible physician, especially in the first months of treatment.
It has to be considered that, with the presence of micro-plastic, i.e. PEG particles, in the food chain and in cosmetics, anti-PEG antibodies are found even in individuals who have never been treated with PEGylated drugs. Do we have to worry about these "constitutive" anti-PEG antibodies as potential modifiers of our immune system or as sensitizers for immunologic reactions against PEGylated drugs? Gupta et al. provide preliminary data to answer this question by showing that the presence of anti-PEG antibodies at baseline did not affect Pegvaliase safety in a subgroup of their PKU probands. However, further research is definitely needed to explore the role of "baseline" anti-PEG antibodies in the general population.
No treatment can exist without any potential side effect. The article by Gupta et al. extensively describes the immunologic reactions associated with a new promising treatment for an old disease, namely PKU. Their study may serve as a template for further studies on the efficacy and safety of PEGylated biologics and as a valuable resource for clinicians, who consider the use of Pegvaliase in their adult PKU patients.
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